Biomissile

About Biomissile

Biomissile is a clinical-stage biotechnology company founded in 2020 by Dr. Chao Tu and Dr. Tianlei Ying. Headquartered in Suzhou, China, with additional operations in Shanghai for research and development and Boston for business development and clinical trials, the company specializes in developing treatments for diseases with no effective therapies, such as solid tumors, autoimmune diseases, and infectious diseases.

The company's business model revolves around its proprietary antibody discovery and optimization platforms. These include the Fully Human Domain Antibody Display Platform (UDABTM), a multi-specifics platform (UDAB-MTM), and phage, yeast, and mammalian cell display platforms. These technologies are designed to rapidly discover and generate multi-specific antibodies. A key focus is on developing next-generation natural killer (NK) cell engagers to overcome resistance associated with traditional antibody-drug conjugates (ADCs) by activating immune cells at the tumor site. The company has also developed an inhalable technology for delivering its UDAB molecules to the respiratory system.

Biomissile's therapeutic pipeline includes over 10 innovative biologics, with its lead product, BM-230, an NK cell engager, in Phase I clinical trials for multiple cancers. The company has raised a total of $53.9M, including a significant Series B funding round of $28.5 million in May 2023, led by Keyuan Industrial Fund with participation from existing investor Fosun Health Capital.